A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-severe Atopic Dermatitis - APG777-201

Apogee Therapeutics Inc.0 个研究点目标入组 471 人开始时间: 2024年5月3日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Have a diagnosis of AD that has been present for >=1 year prior to the Screening visit, • Moderate-to-severe AD at Screening and Baseline visits, • History of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable, • Applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for >=14 days prior to Baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits, • Have completed itch questionnaires in the electronic diary for >=4 of 7 days prior to Baseline visit

•Participation in a prior study with APG777, • Prior treatment with protocol-specified monoclonal antibodies (mAbs), • Has used any AD-related topical medications within 7 days prior to Baseline visit, • Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit

发起方

Apogee Therapeutics Inc.